Cognition Therapeutics Inc. (CGTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Cognition Therapeutics In...

    NASDAQ: CGTX · Real-Time Price · USD
    1.43
    0.10 (7.52%)
    At close: Sep 29, 2025, 3:59 PM
    1.42
    -0.70%
    After-hours: Sep 29, 2025, 05:36 PM EDT

    Cognition Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 266K 252K 235K 93K
    Gross Profit
    		 -266K -252K -235K -93K
    Operating Income
    		 -53.97M -50.72M -43.55M -28.6M
    Interest Income
    		 n/a 27K 22.22M 17.45M
    Pretax Income
    		 -33.97M -25.79M -21.4M -11.72M
    Net Income
    		 -33.97M -25.79M 757K -10.29M
    Selling & General & Admin
    		 12.29M 13.53M 13.23M 10.03M
    Research & Development
    		 41.68M 37.2M 30.32M 18.57M
    Other Expenses
    		 n/a n/a -235K n/a
    Operating Expenses
    		 53.97M 50.72M 43.32M 28.6M
    Interest Expense
    		 25K n/a 28K 893K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 53.97M 50.72M 43.55M 28.6M
    Income Tax Expense
    		 n/a n/a -22.15M -1.43M
    Shares Outstanding (Basic)
    		 39.73M 29.99M 28.99M 22.23M
    Shares Outstanding (Diluted)
    		 39.73M 30.03M 28.99M 22.23M
    EPS (Basic)
    		 -0.85 -0.86 -0.74 -0.73
    EPS (Diluted)
    		 -0.85 -0.86 -0.74 -0.73
    EBITDA
    		 -33.68M -25.51M -21.13M -10.73M
    EBIT
    		 -33.95M -25.76M -21.37M -10.82M
    Depreciation & Amortization
    		 316K 252K 235K 93K

    Add to Watchlist